181 related articles for article (PubMed ID: 35312944)
21. Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).
Barnes DJ; Dutton P; Bruland Ø; Gelderblom H; Faleti A; Bühnemann C; van Maldegem A; Johnson H; Poulton L; Love S; Tiemeier G; van Beelen E; Herbschleb K; Haddon C; Billingham L; Bradley K; Ferrari S; Palmerini E; Picci P; Dirksen U; Strauss SJ; Hogendoorn PCW; Buddingh E; Blay JY; Cleton-Jansen AM; Hassan AB
BMC Cancer; 2022 Jun; 22(1):629. PubMed ID: 35672690
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
23. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
24. Type 4 hypersensitivity development in a case due to mifamurtide.
Şimşek M; Ataş E; Bağrıaçık EÜ; Günal A; Ünay B
Turk J Pediatr; 2020; 62(4):694-699. PubMed ID: 32779428
[TBL] [Abstract][Full Text] [Related]
25. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
26. The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma.
Bellini G; Di Pinto D; Tortora C; Manzo I; Punzo F; Casale F; Rossi F
Curr Cancer Drug Targets; 2017; 17(7):650-656. PubMed ID: 27993113
[TBL] [Abstract][Full Text] [Related]
27. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
28. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
29. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
[TBL] [Abstract][Full Text] [Related]
30. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
31. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.
Harrison DJ; Schwartz CL
Curr Treat Options Oncol; 2017 Apr; 18(4):24. PubMed ID: 28391422
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
34. Total Neoadjuvant vs. Standard Perioperative Cisplatin/ Doxorubicin Chemotherapy in Patients with Extremities Osteosarcoma: A Multi-Center Cohort Study.
Foroughi A; Arefpour AM; Nikoofar A; Sanei M; Mahdavi SH; Javadinia SA
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2369-2374. PubMed ID: 37505768
[TBL] [Abstract][Full Text] [Related]
35. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
Serra M; Scotlandi K; Reverter-Branchat G; Ferrari S; Manara MC; Benini S; Incaprera M; Bertoni F; Mercuri M; Briccoli A; Bacci G; Picci P
J Clin Oncol; 2003 Feb; 21(3):536-42. PubMed ID: 12560446
[TBL] [Abstract][Full Text] [Related]
36. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
37. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
39. Treatment of non-metastatic high-grade osteosarcoma (study of 30 cases treated with Scandinavian osteosarcoma protocol XIV and surgery).
Samardziski M; Zafiroski G; Tolevska C; Zafirova-Ivanovska B; Kostadinova-Kunovska S; Kalicanin-Markovska M
Prilozi; 2008 Dec; 29(2):309-23. PubMed ID: 19259055
[TBL] [Abstract][Full Text] [Related]
40. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
